Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY26 results · Apr–Jun 2025
Ajanta Pharma reported revenue from operations of ₹1,302.65 crore (up 13.8% from Q1 FY25) and net profit of ₹255.34 crore (up 3.9% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,302.65 | 1,144.92 | +13.8% | 1,170.41 | +11.3% |
| Other income | 26.33 | 26.47 | −0.5% | 18.11 | +45.4% |
| Total income | 1,328.98 | 1,171.39 | +13.5% | 1,188.52 | +11.8% |
| Profit before tax | 331.13 | 322.12 | +2.8% | 269.41 | +22.9% |
| Net profit for the period | 255.34 | 245.77 | +3.9% | 225.26 | +13.4% |
| EPS, basic (₹) | 20.44 | 19.54 | +4.6% | 18.00 | +13.6% |
| Net margin (%) | 19.6 | 21.5 | 19.2 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,208.56 | 1,077.27 | +12.2% | 1,013.94 | +19.2% |
| Other income | 40.63 | 28.37 | +43.2% | 17.93 | +126.6% |
| Total income | 1,249.19 | 1,105.64 | +13.0% | 1,031.87 | +21.1% |
| Profit before tax | 328.99 | 310.56 | +5.9% | 228.15 | +44.2% |
| Net profit for the period | 254.97 | 236.03 | +8.0% | 193.43 | +31.8% |
| EPS, basic (₹) | 20.41 | 18.77 | +8.7% | 15.46 | +32.0% |
| Net margin (%) | 21.1 | 21.9 | 19.1 |
Consolidated
- Filed with BSE
- 28 Jul 2025, 16:09 IST
- Board meeting
- 28 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2025, 16:09 IST
- Board meeting
- 28 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE